Anne M Murray1, Elizabeth J Bell2, David E Tupper3, Cynthia S Davey4, Sarah L Pederson2, Elizabeth M Amiot2, Kathleen M Miley5, Lauren McPherson6, Brooke M Heubner7, David T Gilbertson7, Robert N Foley8, Paul E Drawz8, Yelena Slinin9, Rebecca C Rossom10, Kamakshi Lakshminarayan11, Prashanthi Vemuri12, Clifford R Jack12, David S Knopman13. 1. Berman Center for Clinical Research, Minneapolis Medical Research Foundation, Minneapolis, MN; Geriatrics Division, Hennepin County Medical Center, Minneapolis, MN. Electronic address: amurray@bermancenter.org. 2. Berman Center for Clinical Research, Minneapolis Medical Research Foundation, Minneapolis, MN. 3. Department of Psychology and Neuropsychology, Hennepin County Medical Center, Minneapolis, MN. 4. Biostatistical Design and Analysis Center, University of Minnesota Clinical and Translational Science Institute, Minneapolis, MN. 5. Department of Psychiatry, Hennepin County Medical Center, Minneapolis, MN. 6. University of Minnesota Medical School, Minneapolis, MN. 7. Chronic Disease Research Group, Minneapolis Medical Research Foundation, Hennepin County Medical Center, Minneapolis, MN. 8. Nephrology Division, Department of Medicine, University of Minnesota, Minneapolis, MN. 9. Nephrology Division, Department of Medicine, University of Minnesota, Minneapolis, MN; Veterans Affairs Medical Center, Minneapolis, MN. 10. HealthPartners Institute for Education and Research, Minneapolis, MN. 11. Neurology Department, University of Minnesota, Minneapolis, MN; Division of Epidemiology & Community Health, University of Minnesota School of Public Health, Minneapolis, MN. 12. Department of Radiology, Mayo Clinic, Rochester, MN. 13. Department of Neurology, Mayo Clinic, Rochester, MN.
Abstract
BACKGROUND: The Brain in Kidney Disease (BRINK) Study aims to identify mechanisms that contribute to increased risk for cognitive impairment in patients with chronic kidney disease (CKD). We describe the rationale, design, and methods of the study and report baseline recruitment and cognitive function results. STUDY DESIGN: Longitudinal observational cohort study of the epidemiology of cognitive impairment in CKD. The primary aim is to characterize the association between (1) baseline and incident stroke, white matter disease, estimated glomerular filtration rate (eGFR), inflammation, microalbuminuria, and dialysis initiation and (2) cognitive decline over 3 years in a CKD cohort with a mean eGFR<45 mL/min/1.73 m(2). SETTING & PARTICIPANTS: Community-dwelling participants 45 years or older recruited from 4 health systems into 2 groups: reduced eGFR, defined as eGFR<60 mL/min/1.73 m(2) (non-dialysis dependent), and control, defined as eGFR≥60 mL/min/1.73 m(2). PREDICTOR: eGFR group. OUTCOMES: Performance on cognitive function tests and structural brain magnetic resonance imaging. MEASUREMENTS: Sequential cognitive and physical function testing, serum and urine biomarker measurement, and brain magnetic resonance images over 3 years. RESULTS: Of 554 participants, mean age was 69.3 years; 333, 88, and 133 had eGFRs<45 (non-dialysis dependent, nontransplantation), 45 to <60, and ≥60 (controls) mL/min/1.73 m(2), respectively. Mean eGFR in reduced-eGFR participants was 34.3 mL/min/1.73 m(2). Baseline cognitive performance was significantly associated with eGFR in all domains except language. Participants with eGFRs<30 mL/min/1.73 m(2) performed significantly worse than those with eGFRs≥30 mL/min/1.73 m(2) on tests of memory, processing speed, and executive function. Participants with reduced eGFRs overall scored worst on the Immediate Brief Visual-Spatial Memory Test-Revised. LIMITATIONS: Healthy cohort bias, competing risk for death versus cognitive decline. CONCLUSIONS: Cognitive function was significantly worse in participants with eGFRs<30 mL/min/1.73 m(2). Future BRINK analyses will measure risk factors for cognitive decline using the longitudinal data.
BACKGROUND: The Brain in Kidney Disease (BRINK) Study aims to identify mechanisms that contribute to increased risk for cognitive impairment in patients with chronic kidney disease (CKD). We describe the rationale, design, and methods of the study and report baseline recruitment and cognitive function results. STUDY DESIGN: Longitudinal observational cohort study of the epidemiology of cognitive impairment in CKD. The primary aim is to characterize the association between (1) baseline and incident stroke, white matter disease, estimated glomerular filtration rate (eGFR), inflammation, microalbuminuria, and dialysis initiation and (2) cognitive decline over 3 years in a CKD cohort with a mean eGFR<45 mL/min/1.73 m(2). SETTING & PARTICIPANTS: Community-dwelling participants 45 years or older recruited from 4 health systems into 2 groups: reduced eGFR, defined as eGFR<60 mL/min/1.73 m(2) (non-dialysis dependent), and control, defined as eGFR≥60 mL/min/1.73 m(2). PREDICTOR: eGFR group. OUTCOMES: Performance on cognitive function tests and structural brain magnetic resonance imaging. MEASUREMENTS: Sequential cognitive and physical function testing, serum and urine biomarker measurement, and brain magnetic resonance images over 3 years. RESULTS: Of 554 participants, mean age was 69.3 years; 333, 88, and 133 had eGFRs<45 (non-dialysis dependent, nontransplantation), 45 to <60, and ≥60 (controls) mL/min/1.73 m(2), respectively. Mean eGFR in reduced-eGFR participants was 34.3 mL/min/1.73 m(2). Baseline cognitive performance was significantly associated with eGFR in all domains except language. Participants with eGFRs<30 mL/min/1.73 m(2) performed significantly worse than those with eGFRs≥30 mL/min/1.73 m(2) on tests of memory, processing speed, and executive function. Participants with reduced eGFRs overall scored worst on the Immediate Brief Visual-Spatial Memory Test-Revised. LIMITATIONS: Healthy cohort bias, competing risk for death versus cognitive decline. CONCLUSIONS: Cognitive function was significantly worse in participants with eGFRs<30 mL/min/1.73 m(2). Future BRINK analyses will measure risk factors for cognitive decline using the longitudinal data.
Authors: Manjula Kurella; Kristine Yaffe; Michael G Shlipak; Nanette K Wenger; Glenn M Chertow Journal: Am J Kidney Dis Date: 2005-01 Impact factor: 8.860
Authors: Manjula Kurella Tamura; Virginia Wadley; Kristine Yaffe; Leslie A McClure; George Howard; Rodney Go; Richard M Allman; David G Warnock; William McClellan Journal: Am J Kidney Dis Date: 2008-06-30 Impact factor: 8.860
Authors: Tamara G Fong; Michael A Fearing; Richard N Jones; Peilin Shi; Edward R Marcantonio; James L Rudolph; Frances M Yang; Dan K Kiely; Sharon K Inouye Journal: Alzheimers Dement Date: 2009-07-31 Impact factor: 21.566
Authors: Kristine Yaffe; Karla Lindquist; Michael G Shlipak; Eleanor Simonsick; Linda Fried; Caterina Rosano; Suzanne Satterfield; Hal Atkinson; B Gwen Windham; Manjula Kurella-Tamura Journal: Ann Neurol Date: 2008-06 Impact factor: 10.422
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Mary Hannan; Alana Steffen; Lauretta Quinn; Eileen G Collins; Shane A Phillips; Ulf G Bronas Journal: J Nephrol Date: 2018-05-25 Impact factor: 3.902
Authors: Alvin G Thomas; Jessica M Ruck; Ashton A Shaffer; Christine E Haugen; Hao Ying; Fatima Warsame; Nadia Chu; Michelle C Carlson; Alden L Gross; Silas P Norman; Dorry L Segev; Mara McAdams-DeMarco Journal: Transplantation Date: 2019-07 Impact factor: 4.939
Authors: Prashanthi Vemuri; David S Knopman; Clifford R Jack; Emily S Lundt; Stephen D Weigand; Samantha M Zuk; Kaely B Thostenson; Robert I Reid; Kejal Kantarci; Yelena Slinin; Kamakshi Lakshminarayan; Cynthia S Davey; Anne Murray Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: Daniel E Weiner; Sarah A Gaussoin; John Nord; Alexander P Auchus; Gordon J Chelune; Michel Chonchol; Laura Coker; William E Haley; Anthony A Killeen; Paul L Kimmel; Alan J Lerner; Suzanne Oparil; Mohammad G Saklayen; Yelena M Slinin; Clinton B Wright; Jeff D Williamson; Manjula Kurella Tamura Journal: Am J Kidney Dis Date: 2017-06-09 Impact factor: 8.860
Authors: Elsemieke Te Linde; Claudette J M van Roij; Bjӧrn K I Meijers; Henriette De Loor; Roy P C Kessels; Jack F M Wetzels Journal: Kidney360 Date: 2020-09-21
Authors: Meera N Harhay; Dawei Xie; Xiaoming Zhang; Chi-Yuan Hsu; Eric Vittinghoff; Alan S Go; Stephen M Sozio; Jacob Blumenthal; Stephen Seliger; Jing Chen; Rajat Deo; Mirela Dobre; Sanjeev Akkina; Peter P Reese; James P Lash; Kristine Yaffe; Manjula Kurella Tamura Journal: Am J Kidney Dis Date: 2018-05-02 Impact factor: 8.860
Authors: Christine M Burns; David S Knopman; David E Tupper; Cynthia S Davey; Yelena M Slinin; Kamakshi Lakshminarayan; Rebecca C Rossom; Sarah L Pederson; David T Gilbertson; Anne M Murray Journal: J Gerontol A Biol Sci Med Sci Date: 2018-03-02 Impact factor: 6.053